Compare Quest Diagnostics Inc (DGX) vs Global X Defense Tech ETF (SHLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Global X Defense Tech ETF — how do they compare? Quest Diagnostics Inc trades at $204.69 (market cap $22.80B), while Global X Defense Tech ETF trades at $60.5. The key difference: Quest Diagnostics Inc pays a 1.67% dividend while Global X Defense Tech ETF pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, Global X Defense Tech ETF nearer its low. Which is the better fit depends on your goals.
| DGX | SHLD | |
|---|---|---|
Market Cap | $22.80B | — |
Sector | Health | Sector/Thematic |
52-Week High | $216.02 | $78.02 |
52-Week Low | $166.42 | $58.20 |
Enterprise Value | $28.82B | — |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
SHLD (Global X Defense Tech ETF) trades at $60.47, down 1.18% today amid bearish technical signals. The ETF faces selling pressure with moving averages indicating a downtrend, though oscillators remain neutral. Recent news highlights defense sector opportunities from global military spending increases and geopolitical tensions, with SHLD positioned as a diversified play on defense technology innovation across international markets.
Outlook remains mixed with technical weakness offset by positive sector catalysts. Investment opportunity lies in exposure to rising global defense budgets and technological modernization, but risks include political uncertainty and competition from specialized ETFs. The bearish technical setup suggests cautious entry points near support levels may be prudent for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Global X Defense Tech ETF
SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.
Read more on SHLD →
